CD4 and COVID-19: As the majority of PWH enrolled in COVID-19 vaccine trials have had normal CD4 T cell counts (>500 cells/mm3) and few comorbidities [26,27], these immunogenicity results may not be generalizable to the wide spectrum of PWH who are followed in Canadian centres.